Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Arthritis, Rheumatoid;Arthritis, Psoriatic;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Arthritis, Juvenile Rheumatoid;Crohn Disease;Skin Diseases, Papulosquamous, Date of authorisation: 26/07/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Multiple Sclerosis, Date of authorisation: 30/01/2014, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Omnitrope, somatropin, Turner Syndrome;Prader-Willi Syndrome;Dwarfism, Pituitary, Date of authorisation: 12/04/2006, Revision: 22, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Rozanolixizumab, decision type: , therapeutic area: , PIP number: P/0410/2022

Opinion/decision on a Paediatric investigation plan (PIP): Vumerity,Diroximel fumarate (BIIB098), decision type: , therapeutic area: , PIP number: P/0413/2022

Opinion/decision on a Paediatric investigation plan (PIP): Zoliflodacin, decision type: , therapeutic area: , PIP number: P/0381/2022

Opinion/decision on a Paediatric investigation plan (PIP): Xofluza,Baloxavir marboxil, decision type: , therapeutic area: , PIP number: P/0383/2022

Medicinal products for human use: monthly figures - August 2023

Calcium chloride dihydrate/magnesium chloride hexahydrate/malic acid/sodium acetate trihydrate/sodium chloride....potassium chloride : List of nationally authorised medicinal products - PSUSA/00010622/202301